FDA Has Accepted New Multiple Sclerosis Drug Application
The investigational treatment fenebrutinib is being reviewed for both relapsing and progressive forms of multiple sclerosis.
Updated on Sept. 30, 2026 in Stroke
Live Poll
Do you trust that new high-efficacy drugs will improve long-term outcomes for chronic disease patients?
The FDA has accepted a New Drug Application for fenebrutinib, an investigational therapy designed to treat both relapsing and primary progressive multiple sclerosis. If approved, the drug would provide a new option for many of the 1 million Americans currently living with the condition.
Why it matters
This development is significant because fenebrutinib aims to address both acute relapses and chronic disability progression in one therapy. By targeting both, it potentially offers a more comprehensive approach to managing the neurological damage associated with multiple sclerosis.
Clinical evidence from studies including more than 2,700 participants showed fenebrutinib reduced the annualized relapse rate by 51.1% compared to teriflunomide and lowered the risk of disability progression by 12% compared to ocrelizumab.
The players
FDA
The federal agency responsible for evaluating the safety and efficacy of new medical therapies in the United States.
Roche
A multinational healthcare company that researches and manufactures treatments for neurological and immune-related conditions.
The details
Fenebrutinib is a non-covalent Bruton's tyrosine kinase (BTK) inhibitor that functions by modulating B-cell activity within the immune system. Uniquely, the drug is designed to cross the blood-brain barrier to directly inhibit microglia in the central nervous system. This dual-action approach is intended to dampen the inflammation that triggers acute relapses while simultaneously slowing the neurodegeneration that causes long-term disability.
Timeline
February 7, 2026: Results were presented at the ACTRIMS Forum 2026.
April 21, 2026: Data were presented at the AAN Annual Meeting.
September 30, 2026: The FDA officially accepted the New Drug Application for priority review.
Health Landscape
This filing follows a pattern set by the FENtrepid clinical study by seeking to advance a new class of oral inhibitors against established standards of care. It represents a potential shift toward dual-action therapies capable of managing both relapsing and progressive MS phenotypes.
If you are currently managing multiple sclerosis, this development may eventually offer a new oral treatment option for your care plan. It is worth discussing with your neurologist whether your specific symptoms align with the mechanisms of new investigational B-cell therapies.
The takeaway
Fenebrutinib represents a potential advancement in treating MS by targeting both acute relapses and chronic disability progression. Patients should keep track of their relapse frequency and mobility changes to discuss with their neurologist during their next evaluation.
Further reading
Learn more about the latest innovations in managing neurological conditions at our Stroke section.
More information
For additional details on the company's research pipeline, visit the Roche corporate information portal.
Live Poll
Do you trust that new high-efficacy drugs will improve long-term outcomes for chronic disease patients?
